Febrile neutropenia in cancer patients: a literature review
DOI:
https://doi.org/10.33448/rsd-v12i2.40347Keywords:
Febrile neutropenia; Chemotherapy-induced febrile neutropenia; Neutropenia.Abstract
Introduction: Febrile neutropenia is currently a frequently observed condition in the oncology therapy setting. This complication is associated with the use of chemotherapy. Objective: to contribute to the continuous reduction of mortality associated with this condition, through an approach focused on risk stratification and early broad-spectrum antibiotic therapy. Method: A narrative literature review was performed using the Pubmed, Scielo and UptoDate databases. For the search, the descriptors were used: "Febrile Neutropenia"; "Neutropenia in cancer patients"; "Post chemotherapy fever" and "Febrile post chemotherapy neutropenia". The guiding question was: “What risk stratification and treatment are most appropriate for cancer patients with febrile neutropenia?”. Articles between the years 2010 to 2023 were selected. Articles that did not respond to the guiding question were excluded. 237 articles were found, of which 34 matched the pre-established criteria. Results and Discussion: Fever is commonly reported in cancer patients undergoing chemotherapy. In most cases the infectious focus is not found. Individuals with febrile neutropenia are classified according to the severity of the clinical condition, intensity of neutropenia and according to the chemotherapy regimen used. Early recognition and initiation of empirical antibiotic therapy are essential for a good prognosis. It is concluded that adequate risk stratification, diagnosis and therapy in a short period of time lead to a reduction in mortality.
References
Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., Tjan-Heijnen, V. C., Walewski, J., Weber, D. C., Zielinski, C., & European Organisation for Research and Treatment of Cancer (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European journal of cancer (Oxford, England: 1990), 47(1), 8–32. https://doi.org/10.1016/j.ejca.2010.10.013
Ahn, S., Lee, Y. S., Lim, K. S., & Lee, J. L. (2013). Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 21(8), 2303–2308. https://doi.org/10.1007/s00520-013-1787-6
Álvarez, J. C., Cuervo, S. I., Garzón, J. R., Gómez, J. C., Díaz, J. A., Silva, E., Sánchez, R., & Cortés, J. A. (2013). Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy. BMC pharmacology & toxicology, 14, 59. https://doi.org/10.1186/2050-6511-14-59
Barton, C. D., Waugh, L. K., Nielsen, M. J., & Paulus, S. (2015). Febrile neutropenia in children treated for malignancy. The Journal of infection, 71 Suppl 1, S27–S35. https://doi.org/10.1016/j.jinf.2015.04.026
Bellesso, M., Costa, S. F., Chamone, D. A. F., & Llacer, P. E. D. (2010). Triagem para o tratamento ambulatorial da neutropenia febril. Rev. Bras. Hemoter. 32(5). https://doi.org/10.1590/S1516-84842010000500014
Borges, G., Petrarca, C. R., Azambuja, A. A., Hasse, J., Zimath, T., & Barbosa, T. B. R. (2013). Neutropenia febril em pacientes com câncer e baixo risco de complicações: tratamento ambulatorial versus tratamento hospitalar. Rev Bras Oncol Clin. 9(33); 93-5.
Combariza, J. F., Lombana, M., Pino, L. E., & Arango, M. (2015). C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 23(4), 1009–1013. https://doi.org/10.1007/s00520-014-2454-2
Dulisse, B., Li, X., Gayle, J. A., Barron, R. L., Ernst, F. R., Rothman, K. J., Legg, J. C., & Kaye, J. A. (2013). A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. Journal of medical economics, 16(6), 720–735. https://doi.org/10.3111/13696998.2013.782034
Escrihuela-Vidal, F., Laporte, J., Albasanz-Puig, A., & Gudiol, C. (2019). Update on the management of febrile neutropenia in hematologic patients. Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia, 32 Suppl 2(Suppl 2), 55–58.
Ferreira, J. N., Correia, L. R. B. R., Oliveira, R. M., Watanabe, S. N., Possari, J. F., & Lima, A. F. C. (2017). Managing febrile neutropenia in adult cancer patients: an integrative review of the literature. Revista Brasileira de Enfermagem, 70(6), 1301-1308. https://doi.org/10.1590/0034-7167-2016-0247
Fletcher, M., Hodgkiss, H., Zhang, S., Browning, R., Hadden, C., Hoffman, T., Winick, N., & McCavit, T. L. (2013). Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatric blood & cancer, 60(8), 1299–1306. https://doi.org/10.1002/pbc.24485
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J. A., Wingard, J. R., & Infectious Diseases Society of America (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 52(4), e56–e93. https://doi.org/10.1093/cid/cir073
García de Guadiana-Romualdo, L., Español-Morales, I., Cerezuela-Fuentes, P., Consuegra-Sánchez, L., Hernando-Holgado, A., Esteban-Torrella, P., Jiménez-Santos, E., Viqueira-González, M., de Béjar-Almira, Á., & Albaladejo-Otón, M. D. (2015). Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 23(7), 2175–2182. https://doi.org/10.1007/s00520-014-2589-1
Gudiol, C., Royo-Cebrecos, C., Abdala, E., Akova, M., Álvarez, R., Maestro-de la Calle, G., Cano, A., Cervera, C., Clemente, W. T., Martín-Dávila, P., Freifeld, A., Gómez, L., Gottlieb, T., Gurguí, M., Herrera, F., Manzur, A., Maschmeyer, G., Meije, Y., Montejo, M., Peghin, M., & BICAR Study Group (2017). Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrobial agents and chemotherapy, 61(8), e00164-17. https://doi.org/10.1128/AAC.00164-17
Gudiol, C., Aguilar-Guisado, M., Azanza, J. R., Candel, F. J., Cantón, R., Carratalà, J., Garcia-Vidal, C., Jarque, I., Lizasoain, M., Gil-Bermejo, J. M., Ruiz-Camps, I., Sánchez-Ortega, I., Solano, C., Suárez-Lledó, M., Vázquez, L., & de la Cámara, R. (2020). Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enfermedades infecciosas y microbiologia clinica (English ed.), 38(4), 174–181. https://doi.org/10.1016/j.eimc.2019.01.013
Hoff, P. M. G., Diz, M. D. P. E., Testa, L., & Mark, P.M. (2013) Manual de condutas em oncologia (2a ed.), 335-45.
Instituto Nacional de Câncer Jose Alencar Gomes da Silva (INCA). (2015). Tratamento do câncer no SUS. Rio de Janeiro, 94-8.
Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., Herrstedt, J., & ESMO Guidelines Committee (2016). Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Annals of oncolog : official journal of the European Society for Medical Oncology, 27(suppl 5), v111–v118. https://doi.org/10.1093/annonc/mdw325
Laskey, R. A., Poniewierski, M. S., Lopez, M. A., Hanna, R. K., Secord, A. A., Gehrig, P. A., Lyman, G. H., & Havrilesky, L. J. (2012). Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecologic oncology, 125(3), 625–630. https://doi.org/10.1016/j.ygyno.2012.03.015
Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical reviews in oncology/hematology, 90(3), 190–199. https://doi.org/10.1016/j.critrevonc.2013.12.006
Mikulska, M., Viscoli, C., Orasch, C., Livermore, D. M., Averbuch, D., Cordonnier, C., Akova, M., & Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID (2014). Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. The Journal of infection, 68(4), 321–331. https://doi.org/10.1016/j.jinf.2013.12.006
Paganini, H., Santolaya, de P. M. E., Álvarez, M., Araña Rosaínz, M. de J., Arteaga Bonilla, R., Bonilla, A., Caniza, M., Carlesse, F., López, L. P., Dueñas de Chicas, L., de León, T., del Pont, J. M., Melgar, M., Naranjo, L., Odio, C., Rodríguez, M., & Scopinaro, M. (2011). Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Revista chilena de infectología, 28(Supl. 1), 10-38. https://dx.doi.org/10.4067/S0716-10182011000400003
Pathak, R., Giri, S., Aryal, M. R., Karmacharya, P., Bhatt, V. R., & Martin, M. G. (2015). Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 23(3), 615–617. https://doi.org/10.1007/s00520-014-2553-0
Pêcheux, M. (2017). Análise do discurso. Ponte editores.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., et al. (2018). Metodologia da pesquisa cientifica. [free e-book]. Santa Maria.
Ram, R., Halavy, Y., Amit, O., Paran, Y., Katchman, E., Yachini, B., Kor, S., Avivi, I., & Ben-Ami, R. (2018). Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 67(8), 1153–1160. https://doi.org/10.1093/cid/ciy258
Rivera-Salgado, D., Valverde-Muñoz, K., & Ávila-Agüero, M. L. (2018). Neutropenia febril en niños con cáncer: manejo en el servicio de emergencias [Febrile neutropenia in cancer patients: management in the emergency room]. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia, 35(1), 62–71. https://doi.org/10.4067/s0716-10182018000100062
Rosa, R. G., Goldani, L. Z., & dos Santos, R. P. (2014). Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis 14, 286. https://doi.org/10.1186/1471-2334-14-286
Salar, A., Haioun, C., Rossi, F. G., Duehrsen, U., Pettengell, R., Johnsen, H. E., Jaeger, U., Verhoef, G., Schwenkglenks, M., Bacon, P., Bendall, K., & Lugtenburg, P. J. (2012). The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leukemia research, 36(5), 548–553. https://doi.org/10.1016/j.leukres.2012.02.002
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K., Strasfeld, L., & Flowers, C. R. (2018). Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 36(14), 1443–1453. https://doi.org/10.1200/JCO.2017.77.6211
Trecarichi, E. M., Pagano, L., Martino, B., Candoni, A., Di Blasi, R., Nadali, G., Fianchi, L., Delia, M., Sica, S., Perriello, V., Busca, A., Aversa, F., Fanci, R., Melillo, L., Lessi, F., Del Principe, M. I., Cattaneo, C., Tumbarello, M., & HaematologicMalignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) group, Italy (2016). Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. American journal of hematology, 91(11), 1076–1081. https://doi.org/10.1002/ajh.24489
Weycker, D., Barron, R., Kartashov, A., Legg, J., & Lyman, G. H. (2014). Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners, 20(3), 190–198. https://doi.org/10.1177/1078155213492450
White, L., & Ybarra, M. (2014). Neutropenic fever. Emergency medicine clinics of North America, 32(3), 549–561. https://doi.org/10.1016/j.emc.2014.04.002
Yasuda, T., Suzuki, R., Ishikawa, Y., Terakura, S., Inamoto, Y., Yanada, M., Nagai, H., Ozawa, Y., Ozeki, K., Atsuta, Y., Emi, N., & Naoe, T. (2013). Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases, 17(6), e385–e390. https://doi.org/10.1016/j.ijid.2012.12.005
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Luana Medeiros Limberger; Jair Alves Bonfim Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
